Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

類似資料

• Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
  著者:: Kubitza, Dagmar, 等
  出版事項: (2010)
• Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
  著者:: Mueck, Wolfgang, 等
  出版事項: (2013)
• Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
  著者:: Zhao, Xia, 等
  出版事項: (2009)
• Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
  著者:: Mueck, Wolfgang, 等
  出版事項: (2013)
• Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
  著者:: Kubitza, Dagmar, 等
  出版事項: (2007)